Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.87)
# 1,571
Out of 5,149 analysts
46
Total ratings
40%
Success rate
55.57%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCOY Decoy Therapeutics | Initiates: Buy | $2.5 | $0.66 | +278.73% | 1 | Jan 23, 2026 | |
| NXTC NextCure | Upgrades: Buy | $18 | $12.04 | +49.50% | 1 | Nov 7, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $13.51 | +11.03% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $1.89 | +905.29% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $13.30 | +125.56% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.06 | +1,975.47% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $8.67 | +176.82% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $13.79 | +806.45% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $3.35 | +437.31% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $2.11 | +800.47% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.19 | - | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $79 | $156.09 | -49.28% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $103.37 | +49.95% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $29.00 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.09 | +709.06% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $3.12 | +57,592.31% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $34.39 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.53 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.80 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $2.68 | +55,870.15% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.12 | +80,257.14% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $9.49 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $11.19 | +1,374.53% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $5.29 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $0.98 | - | 2 | Jan 4, 2017 |
Decoy Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $2.5
Current: $0.66
Upside: +278.73%
NextCure
Nov 7, 2025
Upgrades: Buy
Price Target: $18
Current: $12.04
Upside: +49.50%
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $13.51
Upside: +11.03%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $1.89
Upside: +905.29%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $13.30
Upside: +125.56%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.06
Upside: +1,975.47%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $8.67
Upside: +176.82%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $13.79
Upside: +806.45%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $3.35
Upside: +437.31%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $2.11
Upside: +800.47%
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.19
Upside: -
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $156.09
Upside: -49.28%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $103.37
Upside: +49.95%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $29.00
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $3.09
Upside: +709.06%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $3.12
Upside: +57,592.31%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $34.39
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.53
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $4.80
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $2.68
Upside: +55,870.15%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.12
Upside: +80,257.14%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $9.49
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $11.19
Upside: +1,374.53%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $5.29
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $0.98
Upside: -